Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Molecular Mechanisms of Multiple Sclerosis Pathology
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Mechanisms of Multiple Sclerosis Pathology

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 3113

Special Issue Editors

Prof. Neil J. Scolding

E-Mail Website
Guest Editor
Clinical Neurosciences, University of Bristol, Bristol BS10 5NB, UK
Interests: regeneration and repair in MS; inflammatory brain disease; cell therapies; infective diseases; neurology
Dr. Claire M. Rice

E-Mail Website
Guest Editor
Medical School, University of Bristol, Bristol BS10 5NB, UK
Interests: multiple sclerosis; cell therapy; bone marrow biology; inflammatory brain disease

Special Issue Information

Dear Colleagues,

Despite intense research over many decades, and despite the commonness of the disease, many aspects of the molecular science of multiple sclerosis remain unclear—from the precise molecular pathology of oligodendrocyte, myelin and also neuron and axon damage, through the molecular science of repair, to the molecules dictating disease evolution and, in almost all cases, the molecular mechanisms of thereapies. In this Special Issue, in a range of shorter or more definitive research articles and reviews, we aim to explore the molecular science of multiple sclerosis from a range of angles, building what we hope will be a comprehensive and insightful survey of this field. Since IJMS is a journal of molecular science, purely clinical studies will not be suitable, but clinical submissions with biomolecular experiments are very much encouraged. A better understanding of the mechanisms underlying the development, evolution and treatment of multiple sclerosis will help to rationally identify better therapeutic targets for this difficult disease.

Prof. Neil J. Scolding
Dr. Claire M. Rice
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Multiple sclerosis
  • Molecular pathology
  • MS disease evolution
  • MS therapies

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 1809 KiB  
Article
Repurposing Histaminergic Drugs in Multiple Sclerosis
by Susanna Amadio, Federica Conte, Giorgia Esposito, Giulia Fiscon, Paola Paci and Cinzia Volonté
Int. J. Mol. Sci. 2022, 23(11), 6347; https://doi.org/10.3390/ijms23116347 - 06 Jun 2022
Cited by 5 | Viewed by 2565
Abstract
Multiple sclerosis is an autoimmune disease with a strong neuroinflammatory component that contributes to severe demyelination, neurodegeneration and lesions formation in white and grey matter of the spinal cord and brain. Increasing attention is being paid to the signaling of the biogenic amine [...] Read more.
Multiple sclerosis is an autoimmune disease with a strong neuroinflammatory component that contributes to severe demyelination, neurodegeneration and lesions formation in white and grey matter of the spinal cord and brain. Increasing attention is being paid to the signaling of the biogenic amine histamine in the context of several pathological conditions. In multiple sclerosis, histamine regulates the differentiation of oligodendrocyte precursors, reduces demyelination, and improves the remyelination process. However, the concomitant activation of histamine H1–H4 receptors can sustain either damaging or favorable effects, depending on the specifically activated receptor subtype/s, the timing of receptor engagement, and the central versus peripheral target district. Conventional drug development has failed so far to identify curative drugs for multiple sclerosis, thus causing a severe delay in therapeutic options available to patients. In this perspective, drug repurposing offers an exciting and complementary alternative for rapidly approving some medicines already approved for other indications. In the present work, we have adopted a new network-medicine-based algorithm for drug repurposing called SAveRUNNER, for quantifying the interplay between multiple sclerosis-associated genes and drug targets in the human interactome. We have identified new histamine drug-disease associations and predicted off-label novel use of the histaminergic drugs amodiaquine, rupatadine, and diphenhydramine among others, for multiple sclerosis. Our work suggests that selected histamine-related molecules might get to the root causes of multiple sclerosis and emerge as new potential therapeutic strategies for the disease. Full article
(This article belongs to the Special Issue Molecular Mechanisms of Multiple Sclerosis Pathology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop